newsfilter
← Latest News
GlobeNewswire·

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out expected by year-end 2025 UTRECHT, The